Tidal Investments LLC Has $14.10 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Tidal Investments LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 36.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 152,591 shares of the biopharmaceutical company’s stock after buying an additional 41,127 shares during the quarter. Tidal Investments LLC’s holdings in Gilead Sciences were worth $14,095,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. HHM Wealth Advisors LLC raised its position in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences in the fourth quarter valued at about $28,000. Crews Bank & Trust bought a new position in Gilead Sciences in the fourth quarter valued at about $31,000. Stephens Consulting LLC raised its position in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new position in Gilead Sciences in the fourth quarter valued at about $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 target price for the company. Bank of America raised their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, Piper Sandler raised their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Trading Up 2.2%

Shares of Gilead Sciences stock opened at $102.50 on Monday. The stock has a market capitalization of $127.50 billion, a PE ratio of 277.03, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The stock has a 50 day moving average price of $105.75 and a two-hundred day moving average price of $99.84. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.32) EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 3.08%. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 25,429 shares of company stock worth $2,894,445. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.